Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2024-11-08 Major Shareholding Noti…
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
Disclosure of large shareholding in Nykode Therapeutics ASA
Major Shareholding Notification Classification · 99% confidence The document explicitly states it is a 'Disclosure of large shareholding' and details a transaction where an entity (Norda ASA) acquired shares, resulting in a total holding that crosses a significant threshold (10.1% of total outstanding shares). This directly relates to changes in significant share ownership levels. Therefore, the appropriate classification is Major Shareholding Notification (MRQ). The document is short (613 chars), but its content is a direct notification of a shareholding change, not an announcement about the publication of a separate report.
2024-11-08 English
Nykode Therapeutics – Webcast Invitation
Regulatory Filings Classification · 91% confidence The document is titled "Company Announcement" and explicitly serves as a "Webcast Invitation" for Nykode Therapeutics to provide an update on a specific product (VB10.NEO). It details the date, time, and link for the webcast and Q&A session. This is not a full financial report (like 10-K or IR), nor is it a formal earnings release (ER) which typically contains summarized financial figures. It is an announcement inviting stakeholders to an event where updates will be discussed. Since it is an invitation to discuss company developments, it most closely aligns with a general corporate communication or an announcement related to investor relations activities, but it is not a standard regulatory filing like RNS or a specific report type. Given the context of providing updates via a webcast, it functions as a general corporate communication. However, none of the provided codes perfectly match a 'Webcast Invitation'. It is not a Call Transcript (CT) as it is an invitation, not the transcript itself. It is not an Earnings Release (ER) as it is not the financial results announcement. It is a communication aimed at investors regarding company progress. In the absence of a specific 'Investor Event Invitation' code, and considering it is a direct communication about company progress intended for investors, it is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if the webcast content is assumed to be a presentation, but the text itself is just the invitation. Given the nature of inviting people to hear updates, and that it's a short, non-financial report announcement, RNS (Regulatory Filings / General Announcement) is the most appropriate fallback, as it is a formal company announcement.
2024-11-07 English
Nykode Therapeutics – Webcast Invitation
Report Publication Announcement Classification · 99% confidence The document is titled 'Nykode Therapeutics – Webcast Invitation' and explicitly invites recipients to a webcast scheduled for November 8, 2024, to provide an update on a specific product (VB10.NEO). This is an announcement about an upcoming event where information (likely related to earnings or clinical updates) will be discussed, rather than the full report itself (like an ER or IR). Since the primary purpose is to announce a call/presentation event, the most fitting category is 'Call Transcript' (CT) if the transcript were present, but since this is the *invitation* to the call, and it doesn't fit neatly into the other specific categories (like ER, IP, or DIV), it functions as a general announcement regarding investor communication. However, given the options, an invitation to an earnings/update call is most closely related to the context of a Call Transcript (CT) or potentially an Investor Presentation (IP) if slides were attached. Since it is purely an invitation to a live event for updates, and not the presentation slides (IP) or the formal earnings release (ER), it is best classified as a general announcement related to investor relations communication. In the absence of a specific 'Webcast Invitation' code, and noting that it precedes a Q&A session often associated with earnings, it is closest to a Call Transcript (CT) context, but since it is only the invitation, 'Regulatory Filings' (RNS) serves as the best general fallback for non-standard investor communications that don't fit the specific report types.
2024-11-07 English
Nykode Therapeutics to Regain Control of VB10.NEO Program
Regulatory Filings Classification · 100% confidence The document is a formal announcement titled "Company Announcement" detailing a significant business event: Nykode Therapeutics regaining control of the VB10.NEO program after Genentech terminated a collaboration agreement. It includes details about the termination date, financial implications (no refund required), CEO commentary, and plans for a future webcast. This type of announcement, which details a major corporate development (licensing/collaboration change) but is not a full financial report (10-K, IR) or a standard earnings release (ER), fits best under the general category for significant corporate news that doesn't fit elsewhere, or potentially a financing/transaction update. Since it is a specific announcement about a change in asset control/licensing, it is not a standard M&A (TAR) but rather a corporate action. Given the options, it is a significant corporate announcement. It is too detailed to be a simple Regulatory Filing (RNS) fallback, and it is not a Director's Dealing (DIRS), Dividend (DIV), or Capital Change (SHA/CAP). It is most closely related to a major business development update. Since there isn't a specific 'Business Development Update' code, and it's not a standard financial report, the most appropriate classification among the provided specific codes is difficult. However, it is a formal announcement of a material event. If we consider the options, it is not a proxy (PSI), remuneration (DEF 14A), or management discussion (MDA). It is a material corporate event announcement. Given the context of corporate filings, this type of announcement often falls under general regulatory disclosure. Since it is a specific, material announcement that doesn't fit the other specific categories (like DIRS, DIV, ER, 10-K), it is best classified as a Regulatory Filing (RNS) as a catch-all for significant, non-standard disclosures, or potentially a Capital/Financing Update (CAP) if the regaining of IP is viewed as a capital structure change, but it's primarily a licensing termination. Given the nature of the announcement (a material corporate event disclosure), RNS is the safest fallback, but let's re-evaluate if it fits TAR (M&A Activity). It is a termination of a collaboration, not a merger or takeover bid, so TAR is weak. It is a formal announcement, not a report itself, so RPA is unlikely. I will classify it as RNS as a general regulatory announcement of a material event that doesn't fit the highly specific categories like DIRS, DIV, or ER.
2024-11-07 English
Nykode Therapeutics to Regain Control of VB10.NEO Program
Regulatory Filings Classification · 100% confidence The document is a press release dated November 7, 2024, announcing that Nykode Therapeutics received notification from Genentech regarding the termination of a collaboration agreement for the VB10.NEO cancer vaccine program. It details the implications of this termination (regaining control of IP) and mentions a planned webcast for further details. This type of announcement, which is a significant corporate event but not a formal periodic financial report (like 10-K or IR) or a specific transaction report (like DIRS or POS), falls best under the general category for regulatory announcements that don't fit elsewhere, which is Regulatory Filings (RNS). It is a formal stock exchange announcement ('This stock exchange announcement was published...'). It is too detailed to be a simple Report Publication Announcement (RPA) which usually just points to another document.
2024-11-07 English
Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at PEGS Europe
Regulatory Filings Classification · 99% confidence The document is titled "Company Announcement" and details new scientific findings related to the company's inverse vaccine platform presented at the PEGS Europe conference. It discusses scientific data, potential applications (MS treatment), quotes the Chief Scientific Officer, and includes standard boilerplate sections like 'About Nykode Therapeutics' and 'Forward-looking statements'. This format is characteristic of a press release announcing scientific or operational updates, which typically falls under an Earnings Release (ER) if it contains key financial highlights, or more generally, a Regulatory Filing (RNS) if it's a non-financial operational update. Since this is a scientific/clinical update announcement rather than a formal financial report (like 10-K or IR) or a transcript (CT), and it is an official company announcement, the most appropriate general category for significant, non-mandated regulatory updates that don't fit other specific codes is Regulatory Filings (RNS). It is not a formal Earnings Release (ER) as it focuses purely on scientific data presentation, not period financial results. It is also too detailed to be a simple Report Publication Announcement (RPA).
2024-11-06 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.